本文已被:浏览 1433次 下载 329次
投稿时间:2024-01-03 网络发布日期:2024-02-20
投稿时间:2024-01-03 网络发布日期:2024-02-20
中文摘要: 胃癌是一种严重危害人类健康的恶性肿瘤。Claudin18. 2(CLDN18. 2)是一种跨膜蛋白,作为紧密连接的主要成分,在维持屏障功能中发挥重要作用。在正常生理条件下,CLDN18. 2在健康组织中不表达,在胃黏膜的分化上皮细胞中特异性表达。近年来研究发现,CLDN18. 2也可在胃癌、食管癌、卵巢癌、胰腺癌、肺癌、乳腺癌等恶性肿瘤中高表达或异位激活。基于其特异性表达的特点,CLDN18. 2已经成为抗胃癌药物研发中的明星靶点。本文对CLDN18. 2在胃癌中表达特点、调控方式、临床病理特征以及靶向CLDN18. 2的临床药物研究进展作一综述。
Abstract:Gastric cancer is a malignant tumor that seriously endangers human health. Claudin18.2 (CLDN18.2) is a transmembrane protein and a main component of tight junctions that plays an important role in maintaining barrier function. Under normal physiological conditions, CLDN18.2 is not expressed in healthy tissues, but it is expressed in differentiated epithelial cells of the gastric mucosa. With the progress of research, it has been found that CLDN18.2 is highly expressed or ectopically activated in primary malignant tumors such as gastric cancer, esophageal cancer, ovarian cancer, pancreatic cancer, lung cancer, and breast cancer. Due to its potential for specific expression, CLDN18.2 has become a new emerging target in anti- tumor drug development. This article reviews the expression characteristics, regulation and clinical pathological features, of CLDN18.2 in gastric cancer, and the progress of clinical drug research targeting CLDN18.2.
keywords: Claudin18.2 Gastric cancer Targeted therapy Monoclonal antibodies Bispecific antibodies Chimeric antigen receptor T cells Antibody- drug conjugates
文章编号: 中图分类号:R735.2 文献标志码:A
基金项目:江苏省科技计划项目 (BE20200723)
Author Name | Affiliation |
WANG Qiangcheng, BAO Jun | Department of Medical Oncology, The Affiliated Cancer Hospital of Nanjing Medical University, Nanjing, Jiangsu 210009, China |
引用文本:
王羌成,鲍军.Claudin18.2——胃癌治疗的新兴靶点[J].中国临床研究,2024,37(2):171-176.
王羌成,鲍军.Claudin18.2——胃癌治疗的新兴靶点[J].中国临床研究,2024,37(2):171-176.